Satellos Bioscience (MSLE) analyst forecast and price target
Analyst forecast
Consensus of 9 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Craig-Hallum | Initiated Coverage | Buy | $24.00 | Oct 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Aug 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $11.00 | Jul 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 | May 18, 2026 |
| Guggenheim | Initiated Coverage | Buy | $23.00 | Apr 28, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $20.00 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 from $1.20 | Mar 30, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Mar 11, 2026 |
Frequently asked questions
Is MSLE a buy, sell, or hold?
Analysts covering Satellos Bioscience currently average a Buy rating: 9 buy, 0 hold and 0 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on MSLE?
On Oct 8, 2026, Craig-Hallum initiated coverage of Satellos Bioscience at Buy with a price target of $24.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.